The Delaware Supreme Court has upheld the dismissal of a derivative suit targeting the board of AbbVie Inc. over an aborted buyout of Shire, which ended up costing the Chicago-based drugmaker more than $1.6 billion.

A three-judge panel of the high court Monday upheld, by order, a Chancery Court decision from July that dismissed the suit on demand futility grounds, finding that the directors did not face a substantial risk of liability for their role in scuttling the $55 million deal. The two-sentence order, signed by Justice Karen L. Valihura, affirmed on the basis of the Chancery Court’s July 10 ruling and did not detail any independent reasoning from the Supreme Court.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]